<DOC>
	<DOCNO>NCT02896985</DOCNO>
	<brief_summary>This multi-center study explore relationship recapture response escalation weekly adalimumab trough adalimumab concentration escalation patient experience lack response ( LOR ) .</brief_summary>
	<brief_title>Observational Study Evaluating Effectiveness Drug Concentration Predict Recapture Response Crohn 's Disease Patients With Loss Response</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Documented diagnosis Crohn 's Disease . Treatment adalimumab , minimum 16 week , per clinical practice , dose 160 mg week 0 , 80 mg week 2 , 40 mg q2w document response define investigator . Current evidence active disease/LOR define PRO2 score &gt; 14 presence active inflammation ( confirm CRP &gt; 5 and/or fecal calprotectin great 250Âµg/g . Ability subject participate fully aspects clinical trial . Written informed consent must obtain document . Primary nonresponders 16 week adalimumab therapy . Received investigational drug within 16 week adalimumab therapy . Serious underlying disease CD , opinion investigator , may interfere subject 's ability participate fully study . History alcohol drug abuse , opinion investigator , may interfere subject 's ability comply study procedure . Stools positive Clostridium difficile . Pregnant lactating woman . Current enrolment interventional research study . Presence perianal abdominal abscess .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>C-Reactive Protein ( CRP )</keyword>
	<keyword>Anti-Adalimumab Antibody ( AAA )</keyword>
	<keyword>Therapeutic Drug Monitoring ( TDM )</keyword>
	<keyword>Patient Reported Outcome 2 ( PRO 2 )</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Harvey Bradshaw Index ( HBI )</keyword>
</DOC>